Endocrine Abstracts

The need for Peer Review of UK endocrine units was agreed by the Clinical Committee of the Society for Endocrinology in 2001. The service is relevant to the agendas of clinical governance in endocrinology, and ensuring good quality universal care across the UK for patients. Peer Review presents an opportunity to improve patient care, support and facilitate service provision and innovation. Since Covid-19 (2020) there has been significant changes to the way we work and peer rev...

Fifty postmenopausal hypothyroid women (age 71.7±5.1 year) had been under replacement L-T4 therapy for 4.4±2.0 years before adding calcium carbonate (CC) (taken 1–2 h after L-T4). CC and tablet L-T4 were taken for the subsequent 2.3±1.1 years. Because serum TSH increased compared to L-T4 taken alone (3.33±1.0 vs 2.0±0.5 mU/l (baseline), P<0.001), with 9/50 having TSH values >4.12 mU/l, we instructed all 50 women to postpone CC aft...

Background: Prostate cancer (PCa) is the fifth leading cause of cancer-related death worldwide. The main pharmacological strategy for this pathology is the blockade of the androgen receptor signalling pathway, commonly known as androgen-deprivation therapy. However, some of the patients does no longer respond to this hormonal therapy. Therefore, finding novel therapeutic strategies to tackle PCa, especially its most advanced phenotype [i.e., castration-resistant prostate cance...

High levels of macrophage inflammatory proteins (MIP1α and MIP1β), related to the recruitment of Th1 and Th2 cells, respectively, have been evidenced in some organ and non organ-specific autoimmune diseases. CXCL10/IP10 has been evidenced in patients with autoimmune thyroid disease (ATD) and in Addison’s disease (AD); MIP1α and MIP1β chemokines have not been so far evaluated in these diseases.Aim: To evaluate plasmatic levels MIP...

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary tumour syndrome inherited in an autosomal dominant manner and characterized by a predisposition to a multitude of endocrine neoplasms primarily of parathyroid, enteropancreatic, and anterior pituitary origin, as well as nonendocrine neoplasms. However, thyroid cancer is not part of this syndrome. Case details: We report the case of a 36-year-old man diagnosed with primary hyper...

It is well known that insulin resistance (IR) is associated with polycystic ovary syndrome (PCOS). Oxidative stress (OS) is, in turn, related to IR, with a vicious cycle. PCOS patients presented higher circulating concentrations of oxidative stress products such as homocysteine, malondialdehyde, an increase of superoxide dismutase and reduction of antioxidants such as glutathione and paraoxonase-1 activity. Most studies however concerned obese PCOS subjects. The physiopatholog...

First generation somatostatin receptor ligands (SRL) are the first-line drugs in primary acromegaly treatment or after surgical failure in patients with active acromegaly. In previous studies we confirmed the association of the expression of SSTR2, Ki67 and E-cadherin (CDH1) in responsive GH-secreting adenomas response to SRL. Moreover, E-cadherin showed a greater predictive capacity than most of the markers described. Loss of E-cadherin is a typical mark of ...

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.Materials and methods: We treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, prog...

The regulation of insulin-like factor 3 (INSL3) secretion from Leydig cells is still incompletely clarified. In this study we measured INSL3 serum levels in transsexual men under estrogen (E) and antiandrogen therapy or after orchiectomy. The effects of gonadotropins on testicular secretion in vitro was also evaluated.Methods: Blood samples were obtained from 14 transsexual men under long-term E (n=5) or E plus cyproterone acetate (E+CPA, <...

Raloxifene (RAL) is a selective estrogen receptor (ER) modulator (SERM) proposed for chemoprevention of breast cancer and osteoporosis. SERMs exert agonist–antagonist effects depending on tissue or ERs expressed. RAL induces apoptosis in both androgen-dependent and independent cell lines, suggesting a selective activation of ERβ and prevalent antagonist effect on ERα in prostate cells (PC). In this study we evaluated effects of estradiol (E2) and RAL on epitheli...